Jayson D.A.  Dallas net worth and biography

Jayson Dallas Biography and Net Worth

Dr. Jayson D.A. Dallas M.D. serves as Independent Director of the Company. Dr. Dallas has served on our Board of Directors since February 2017. He has served as President and Chief Executive Officer of Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, since June 2018. Prior to joining Aimmune, he served as the first Chief Commercial Officer and Executive Vice President of Ultragenyx Pharmaceutical, Inc., a publicly held biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, since August 2015. Prior to Ultragenyx, Dr. Dallas served as General Manager of Roche, a healthcare company, in the United Kingdom from January 2013 to July 2015. Before joining Roche, he held two different positions at Genentech, a pharmaceutical company, as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology, from May 2010 to December 2012 in South San Francisco. Earlier in his career, Dr. Dallas worked at Novartis and Pfizer / Pharmacia in the United States and previously at Roche in Switzerland. Dr. Dallas holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa and an M.B.A. from Ashridge Business School in the United Kingdom.

What is Jayson D.A. Dallas' net worth?

The estimated net worth of Jayson D.A. Dallas is at least $837,416.25 as of June 15th, 2021. Dr. Dallas owns 8,375 shares of Arena Pharmaceuticals stock worth more than $837,416 as of April 16th. This net worth approximation does not reflect any other investments that Dr. Dallas may own. Learn More about Jayson D.A. Dallas' net worth.

How do I contact Jayson D.A. Dallas?

The corporate mailing address for Dr. Dallas and other Arena Pharmaceuticals executives is 6154 Nancy Ridge Drive, San Diego CA, 92121. Arena Pharmaceuticals can also be reached via phone at (858) 453-7200 and via email at [email protected]. Learn More on Jayson D.A. Dallas' contact information.

Has Jayson D.A. Dallas been buying or selling shares of Arena Pharmaceuticals?

Jayson D.A. Dallas has not been actively trading shares of Arena Pharmaceuticals in the last ninety days. Most recently, Jayson Donald Alexander Dallas sold 1,223 shares of the business's stock in a transaction on Tuesday, June 15th. The shares were sold at an average price of $66.36, for a transaction totalling $81,158.28. Following the completion of the sale, the director now directly owns 8,375 shares of the company's stock, valued at $555,765. Learn More on Jayson D.A. Dallas' trading history.

Who are Arena Pharmaceuticals' active insiders?

Arena Pharmaceuticals' insider roster includes Vincent Aurentz (VP), Christopher Cabell (CMO), Jayson Dallas (Director), Robert Lisicki (EVP), Amit Munshi (CEO), Tina Nova (Director), and Manmeet Soni (Director). Learn More on Arena Pharmaceuticals' active insiders.

Jayson D.A. Dallas Insider Trading History at Arena Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/15/2021Sell1,223$66.36$81,158.288,375View SEC Filing Icon  
1/19/2021Sell1,327$80.50$106,823.505,308View SEC Filing Icon  
12/8/2020Buy5$66.25$331.256,630View SEC Filing Icon  
6/14/2019Sell1,525$55.90$85,247.505,704View SEC Filing Icon  
See Full Table

Jayson D.A. Dallas Buying and Selling Activity at Arena Pharmaceuticals

This chart shows Jayson Donald Alexander Dallas's buying and selling at Arena Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arena Pharmaceuticals Company Overview

Arena Pharmaceuticals logo
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $99.99
Low: $99.99
High: $99.99

50 Day Range

MA: $97.65
Low: $93.13
High: $99.99

2 Week Range

Now: $99.99
Low: $45.50
High: $100.00

Volume

107 shs

Average Volume

1,561,326 shs

Market Capitalization

$6.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55